Mount Sinai Surgeon Performs First Two Percutaneous Treatments of Abdominal Aortic Aneurysms

Dr. Peter Faries performs minimally invasive procedure that is safer and more accurate than other methods.

New York, NY
 – December 11, 2012 /Press Release/  –– 

Peter Faries, MD, Chief of Vascular Surgery at The Mount Sinai Medical Center, has performed the first two fully percutaneous treatments of Abdominal Aortic Aneurysms (AAA) in the United States using the Incraft™ stent graft system. The procedures were part of an investigational study evaluating the efficacy of the Incraft system.

"This system represents a considerable advancement in the standard of care by improving the quality of treatment the patient receives and the speed of their recovery," said Dr. Faries. "Both patients I've treated so far went home the day after surgery and were fully recovered a month later. When you compare that to traditional treatments where the patient could be looking at a week in the hospital and three months of recovery, this system really provides a remarkable advancement in patient care."

To date 57 procedures have been successfully performed in the United States and Japan. The first two procedures were performed at Mount Sinai on August 28, 2012 and both patients remain in good health.

An AAA is a ballooning of the abdominal aorta, often caused by a weakening of the artery wall as well as high blood pressure. Abdominal aortic aneurysms occur in 5 percent to 7 percent of people age 60 or older, and men are four times more likely to have AAA than women. Every year, more than 15,000 people die of AAA, making it the 13th leading cause of death in the United States. If left untreated, AAAs can rupture or burst which is usually fatal. Repairing an AAA involves replacing or reinforcing the damaged section of the aorta with a synthetic tube, or graft. Traditional surgical options include open abdominal surgery or endovascular surgery, which involves an open incision in the leg to thread the catheter through an artery up to the aorta.

Treating AAAs percutaneously, or via a needle puncture in the skin, eliminates an open incision and exposure of inner organs and tissues, cutting down on risk during the procedure and leading to quicker recovery time. The Incraft system also allows for more accurate positioning of the catheter guiding the graft and is appropriate for a wider range of types and sizes of AAAs.

The Incraft™ is a modification of The TERAMED® AAA Stent-Graft System invented by Michael L. Marin, MD, Professor and Chair of the Department of Surgery at The Mount Sinai Medical Center.

Mount Sinai is one of 50 sites in the United States and Japan participating in the pre-market investigational study, called the Cordis INSPIRATION study. The study is run by Cordis Corporation, a Johnson & Johnson company.

As Chief of Vascular Surgery at Mount Sinai, Dr. Faries is responsible for leading the clinical and academic efforts of the Ruth J. & Maxwell Hauser and Harriet & Arthur Aufses, Jr., MD Department of Surgery's Vascular Division. He is an expert in the treatment of carotid artery disease for the prevention of stroke, and has helped advance the practice of minimally invasive vascular surgery, particularly the use of percutaneous techniques that can effectively improve arterial blood flow without the need for more invasive, traditional open surgery. His practice focuses on percutaneous transluminal angioplasty for the treatment of carotid artery stenosis renovascular hypertension and lower extremity  ischemia, as well as endovascular treatments for thoracic and abdominal aortic aneurisms.

Both a renowned surgeon and an active researcher, Dr. Faries oversees numerous clinical trials investigating new treatments for vascular disorders. He leads a National Institutes of Health-supported laboratory and a research team studying the root causes of aortic aneurism, his area of expertise, and whether stem cells can treat this condition. Dr. Faries has also studied the use of a filter that protects the brain by capturing plaque debris that comes loose during angioplasty.

Dr. Marin previously had a financial relationship with Cordis, but no longer does.
Dr. Faries has never had a financial relationship with Cordis.

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and by  U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll.  Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place. 

For more information, visit  
Find Mount Sinai on:
Twitter @mountsinainyc

# # #